Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

Skip Navigation

A Phase II Randomized Study of Adjuvant versus NeoAdjuvant Pembrolizumab MK-3475 for Clinically Detectable Stage III-IV High-Risk Melanoma

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03698019

Study #:
STUDY00143860

Start Date:
Jun 24, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03698019

View Complete Trial Details & Eligibility at ClinicalTrials.gov